Q3 EPS Estimates for Kura Oncology Lifted by Analyst

Kura Oncology, Inc. (NASDAQ:KURA) – Analysts at Brookline Capital Markets increased their Q3 2026 EPS estimates for shares of Kura Oncology in a research note issued on Wednesday, August 12th. Brookline Capital Markets analyst L. Cann now expects that the company will earn ($0.99) per share for the quarter, up from their prior estimate of ($1.06). The consensus estimate for Kura Oncology’s current full-year earnings is ($3.23) per share. Brookline Capital Markets also issued estimates for Kura Oncology’s Q4 2026 earnings at ($0.89) EPS, FY2026 earnings at ($3.48) EPS, FY2027 earnings at ($2.53) EPS, FY2028 earnings at ($2.36) EPS and FY2030 earnings at $17.13 EPS.

KURA has been the subject of a number of other research reports. Citigroup restated a “market outperform” rating on shares of Kura Oncology in a research note on Thursday, May 28th. Sanford C. Bernstein set a $24.00 price objective on Kura Oncology in a research note on Monday, June 15th. Wedbush raised their target price on Kura Oncology from $36.00 to $38.00 and gave the stock an “outperform” rating in a research report on Thursday, August 13th. Wells Fargo & Company set a $24.00 price target on Kura Oncology in a research note on Thursday, June 4th. Finally, Oppenheimer set a $24.00 price target on Kura Oncology in a research report on Thursday, May 28th. Ten research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $25.62.

Kura Oncology Stock Performance

NASDAQ KURA opened at $12.33 on Monday. Kura Oncology has a twelve month low of $6.95 and a twelve month high of $12.85. The company has a quick ratio of 4.71, a current ratio of 4.73 and a debt-to-equity ratio of 0.12. The stock has a market cap of $1.09 billion, a P/E ratio of -3.66 and a beta of 0.38. The company’s 50-day simple moving average is $10.34 and its 200 day simple moving average is $9.39.

Kura Oncology (NASDAQ:KURA) last released its quarterly earnings data on Wednesday, August 12th. The company reported ($0.77) EPS for the quarter, topping analysts’ consensus estimates of ($0.88) by $0.11. Kura Oncology had a negative net margin of 384.30% and a negative return on equity of 207.18%. The company had revenue of $20.87 million during the quarter, compared to the consensus estimate of $20.16 million.

Insider Buying and Selling

In other Kura Oncology news, CEO Troy Edward Wilson bought 100,000 shares of Kura Oncology stock in a transaction dated Monday, August 17th. The shares were acquired at an average cost of $11.12 per share, with a total value of $1,112,000.00. Following the acquisition, the chief executive officer directly owned 379,194 shares of the company’s stock, valued at $4,216,637.28. The trade was a 35.82% increase in their ownership of the stock. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, insider Mollie Leoni sold 84,929 shares of the stock in a transaction that occurred on Thursday, June 18th. The stock was sold at an average price of $9.82, for a total value of $834,002.78. Following the sale, the insider owned 182,345 shares in the company, valued at approximately $1,790,627.90. This trade represents a 31.78% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders own 7.60% of the company’s stock.

Hedge Funds Weigh In On Kura Oncology

A number of institutional investors and hedge funds have recently bought and sold shares of the business. BlackRock Inc. acquired a new stake in shares of Kura Oncology in the second quarter valued at $115,286,000. Suvretta Capital Management LLC lifted its position in Kura Oncology by 5.7% during the 4th quarter. Suvretta Capital Management LLC now owns 8,575,422 shares of the company’s stock worth $89,099,000 after buying an additional 459,422 shares in the last quarter. Vanguard Group Inc. lifted its position in Kura Oncology by 0.7% during the 4th quarter. Vanguard Group Inc. now owns 5,507,627 shares of the company’s stock worth $57,224,000 after buying an additional 39,105 shares in the last quarter. Armistice Capital LLC grew its holdings in Kura Oncology by 5.7% during the 4th quarter. Armistice Capital LLC now owns 4,936,000 shares of the company’s stock worth $51,285,000 after acquiring an additional 264,000 shares during the last quarter. Finally, State Street Corp grew its holdings in Kura Oncology by 47.5% during the 4th quarter. State Street Corp now owns 4,931,090 shares of the company’s stock worth $51,234,000 after acquiring an additional 1,587,959 shares during the last quarter.

Kura Oncology Company Profile

Kura Oncology, Inc (NASDAQ: KURA) is a clinical-stage biopharmaceutical company focused on the discovery and development of targeted oncology therapies. Headquartered in La Jolla, California, the company leverages expertise in molecular biology and precision medicine to identify key drivers of cancer growth and design small-molecule inhibitors that block those pathways. Kura’s research platform integrates genomic insights with medicinal chemistry to advance candidates against well-validated targets in solid tumors and hematologic malignancies.

The company’s lead clinical candidate, tipifarnib, is a farnesyltransferase inhibitor being evaluated for the treatment of HRAS-mutant head and neck squamous cell carcinoma and various non-small cell lung cancers.